# Agenovir

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/agenovir

- Industry: Healthcare
- Headquarters: San Francisco, US
- Website: www.agenovir.com
- Total disclosed funding: $11M
- Latest round: Series A (May 17, 2016)
- Investors on record: 3

## About

Agenovir is a biotechnology company focused on developing novel therapeutics to combat viral infections, leveraging advanced genomic technologies to create innovative solutions that address significant market needs.Agenovir specializes in the research and development of antiviral therapies aimed at addressing pressing viral health challenges. The company is headquartered in San Francisco, US. Founded through the expertise of individuals with backgrounds in biotechnology, Agenovir has attracted interest from prominent investors. In a pivotal funding event in May 2016, Agenovir raised USD 10.6 million in a Series A round led by Data Collective, with participation from Bristol-Myers Squibb Company and Lightspeed Venture Partners. This round represented the total amount raised by the company to date.Agenovir is developing a suite of antiviral therapies employing cutting-edge genomic technologies. Their primary focus is on crafting effective drugs for viral diseases, addressing critical health needs across various demographics. The company’s pipeline includes treatments that are carefully designed to maximize efficacy while minimizing side effects, targeted at a wide range of viral infections.The company currently operates on a funding model through investments, including their recent funding round, which provides financial backing for ongoing research and development activities. Revenue generation will be explored through future commercialization of its antiviral products, leveraging strategic partnerships and collaborations within the biotech sector.Agenovir plans to utilize the USD 10.6 million raised in the Series A round to accelerate the development of its antiviral therapies. The company aims to launch new products targeting specific viral infections in the next 18-24 months. Furthermore, Agenovir is looking to expand its market reach into Europe and Asia, focusing on regions that have a high prevalence of viral diseases. As they progress, they intend to establish collaborations with healthcare organizations to facilitate product deployment and enhance market penetration.

## Funding rounds

- Series A, May 17, 2016, $11M — Lightspeed Venture Partners, DCVC, Bristol-Myers Squibb Company

## Investors

- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A
- Bristol-Myers Squibb Company — Series A